laxido orange 13,8 g polvo para solucion oral efg
intergal pharma ireland limited - macrogol 3350; sodio cloruro; sodio bicarbonato; cloruro de potasio - polvo para soluciÓn oral - 13,8 g - macrogol 3350 13,125 g; sodio cloruro 0,3507 g; sodio bicarbonato 0,1785 g; cloruro de potasio 0,0466 g - macrogol, combinaciones con
laxido orange 13,8 g polvo para solucion oral efg , 20 sobres
laxido orange 13,8 g polvo para solucion oral efg , 30 sobres
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - clorhidrato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agentes antitrombóticos - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
inacid d.a.p. 1 mg polvo para solucion inyectable
lundbeck pharmaceuticals ireland limited - indometacina sodica - excipientes: n/a - otros preparados para el corazÓn - otros preparados para el corazón - indometacina
dib 1,0 g sistema de liberacion vaginal para bovino
syn vet-pharma ireland limited - progesterona - sistema de liberaciÓn vaginal - progesterona 1g - progesterona - vacas; novillas
prothromplex 600 ui/20 ml polvo y disolvente para solucion inyectable
shire pharmaceuticals ireland limited - factor ix, antitrombina iii, factor x, factor ii, factor vii, proteinas, protrombina - polvo y disolvente para soluciÓn inyectable - n/a (más de 4 pa) - n/a (más de 4 pa) n/a (más de 4 pa) - factores de la coagulacion ix, ii, vii y x en combinacion
prolusyn 50 microgramos/ml solucion inyectable para bovino
syn vet-pharma ireland limited - gonadorelina acetato - soluciÓn inyectable - gonadorelina acetato 53microgramos/ml - gonadorelina - vacas; novillas
luteoplan 0,25 mg/ml solucion inyectable para bovino y caballos
syn vet-pharma ireland limited - cloprostenol sodico - soluciÓn inyectable - cloprostenol sodico 0,263mg - cloprostenol - yeguas; vacas; novillas
krystexxa
crealta pharmaceuticals ireland limited - pegloticase - gota - preparados antigout - krystexxa es indicado para el tratamiento de graves gota tofácea crónica debilitante en pacientes adultos que también pueden tener compromiso articular erosiva y que no han podido normalizar el ácido úrico del suero con inhibidores de la oxidasa de xantina en la máxima médicamente caso la dosis o para que estos medicamentos están contraindicados.